Navigation Links
Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Date:7/21/2008

LA JOLLA, Calif., July 21 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) announced today that they have initiated research at their facility in La Jolla, California. Zenobia was founded June 1, 2008, is privately funded and moved into their new laboratory and office facilities on July 1. The Zenobia team are leaders in the areas of high-throughput structural biology and fragment-based lead discovery (FBLD).

Zenobia will focus on limited population diseases that are traditionally not pursued by larger companies. Zenobia combines the early-stage drug discovery method of FBLD with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. "There is a niche for companies that are passionate about applying innovative approaches to diseases that are not being addressed by mainstream drug discovery organizations," says Dr. Vicki Nienaber, President and founder of Zenobia. "Our mission is to find cures for these patients by working with foundations, granting agencies and leading biologists and clinicians." Zenobia will also provide access to their technology through a limited number of collaborations and partnerships.

Vicki Nienaber is well known for her pioneering work in techniques to find potential drug molecules using fragment-based screening and structure-based drug design. Vicki has managed both drug discovery and pre-clinical development programs. She was recently the Chief Scientific Officer at ActiveSight, a division of Rigaku Americas Corporation, where she built a diverse team of protein biochemistry, X-ray crystallography and drug discovery experts. Before that, Dr. Nienaber was the Senior Director of Lead Discovery and Crystallography at SGX Pharmaceuticals, where she oversaw strategic drug discovery and structural biology alliances with Novartis and Eli Lilly and initiated their internal kinase lead discovery project. While at Abbott Laboratori
'/>"/>

SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
2. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
3. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
10. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... February 28, Evotec AG (Frankfurt Stock Exchange: EVT) ... study for EVT 302 in smoking,cessation, a reversible ... This double-blind, three-way cross-over study is designed ... and withdrawal symptoms,after short-term deprivation of cigarettes in ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today ... Options in Healthcare Conference on Tuesday,March 4, 2008 at ... being,held at the W Hotel in New York., ... Anadys,Pharmaceuticals, Inc., will present an overview of Anadys and ...
... time, researchers at North Carolina State University have ... physically or chemically different so-called Janus particles ... alternating electrical field is applied to liquid surrounding ... published in the Feb. 8, 2008, edition of ...
Cached Biology Technology:Evotec Starts Phase II in Smoking Cessation with EVT 302 2Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference 2'2-faced' particles act like tiny submarines 2
(Date:7/9/2014)... derived from the oils produced by algae may offer ... this goal, optimization of cost effective strategies for large-scale ... needed. Sapphire Energy has developed an innovative solution to ... systems, described in Industrial Biotechnology , a peer-reviewed ... is available on the Industrial Biotechnology ...
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... usually announce themselves with pain and fever but often can ... that are sneaky and hard to beat. Now, scientists have ... of tiny DNA pyramids. Published in the journal ACS ... can flag bacteria and kill more of them than medicine ... some infectious pathogens can lie in wait, undetectable in the ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Bacteria hijack plentiful iron supply source to flourish 2
... genes significantly affect variation in voter turnout, shedding new ... in the political system. The research, conducted by ... UC San Diego) and psychologist Laura A. Baker (of ... of the American Political Science Review , a ...
... from research groups around Australia, the report includes chapters ... focus on steps that can be taken to adjust ... to the Farm Writers Association of NSW in Sydney ... Howden, said it was time for agriculture to start ...
... through a tropical or temperate forest immediately impresses us ... plant world, but our knowledge of how plants are ... Now, with data emerging from many genome sequencing projects, ... architecture at the molecular level. This knowledge has ...
Cached Biology News:Why do people vote? Genetic variation in political participation 2How to build a plant 2How to build a plant 3
GlutaMAX-I Supplement...
Chemically Defined Lipid Concentrate...
... Cell Dissociation Buffers are membrane-filtered isotonic ... chelating agents and cell-conditioning agents in ... salt solution or Ca2+- and ... of mammalian cells from support substrates ...
... g Blocking Reagent , 2 x 50 ml 10X ... , 0.2 ml BL21 glycerol stock , 0.2 ... stock , 1010 pfu T7Select Positive Control Lysate , ... l S-protein HRP Conjugate , 2 ml T7Select S-protein ...
Biology Products: